Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I

Ebenezer Ojo; Zied Hosni; Iyke Onyemelukwe; Lennart Ramakers; Ian Houson; Alastair Florence

doi:10.6084/m9.figshare.9775382.v1

Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I

Ebenezer Ojo, Zied Hosni, Iyke Onyemelukwe, Lennart Ramakers, Ian Houson, Alastair Florence

Research output: Contribution to conference › Poster

40 Downloads (Pure)

Abstract

Why the considerations for Lamivudine?
* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)
* Hepatitis B infections (257 million cases globally, WHO)
* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).

Key research considerations and interests
To the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:
* Translate current batch crystallisation into a continuous process?
* Improve the downstream process-ability by modifying the particle properties?
* Develop miniaturise platforms for accelerated process development?

Original language	English
Number of pages	1
DOIs	https://doi.org/10.6084/m9.figshare.9775382.v1
Publication status	Published - 9 Jul 2019
Event	50th Annual Conference of the British Association of Crystal Growth - London, United Kingdom Duration: 9 Jul 2019 → 11 Jul 2019

Conference

Conference	50th Annual Conference of the British Association of Crystal Growth
Country/Territory	United Kingdom
City	London
Period	9/07/19 → 11/07/19

Keywords

autonomous platform
crystallisation
anti-retroviral
Lamivudine
process development

Access to Document

10.6084/m9.figshare.9775382.v1Licence: CC BY 4.0

Ojo-etal-2019-Developing-process-understanding-for-continuous-manufacturing-of-LamivudineFinal published version, 1.59 MBLicence: CC BY 4.0

Cite this

@conference{5e6806cbe6ac4f32849668b611c44ad6,

title = "Developing process understanding for continuous manufacturing of Lamivudine (Epivir{\textregistered}) Stable Form I",

abstract = "Why the considerations for Lamivudine?* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)* Hepatitis B infections (257 million cases globally, WHO)* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).Key research considerations and interestsTo the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:* Translate current batch crystallisation into a continuous process?* Improve the downstream process-ability by modifying the particle properties?* Develop miniaturise platforms for accelerated process development?",

keywords = "autonomous platform, crystallisation, anti-retroviral, Lamivudine, process development",

author = "Ebenezer Ojo and Zied Hosni and Iyke Onyemelukwe and Lennart Ramakers and Ian Houson and Alastair Florence",

year = "2019",

month = jul,

day = "9",

doi = "10.6084/m9.figshare.9775382.v1",

language = "English",

note = "50th Annual Conference of the British Association of Crystal Growth ; Conference date: 09-07-2019 Through 11-07-2019",

}

TY - CONF

T1 - Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I

AU - Ojo, Ebenezer

AU - Hosni, Zied

AU - Onyemelukwe, Iyke

AU - Ramakers, Lennart

AU - Houson, Ian

AU - Florence, Alastair

PY - 2019/7/9

Y1 - 2019/7/9

N2 - Why the considerations for Lamivudine?* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)* Hepatitis B infections (257 million cases globally, WHO)* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).Key research considerations and interestsTo the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:* Translate current batch crystallisation into a continuous process?* Improve the downstream process-ability by modifying the particle properties?* Develop miniaturise platforms for accelerated process development?

AB - Why the considerations for Lamivudine?* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)* Hepatitis B infections (257 million cases globally, WHO)* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).Key research considerations and interestsTo the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:* Translate current batch crystallisation into a continuous process?* Improve the downstream process-ability by modifying the particle properties?* Develop miniaturise platforms for accelerated process development?

KW - autonomous platform

KW - crystallisation

KW - anti-retroviral

KW - Lamivudine

KW - process development

U2 - 10.6084/m9.figshare.9775382.v1

DO - 10.6084/m9.figshare.9775382.v1

M3 - Poster

T2 - 50th Annual Conference of the British Association of Crystal Growth

Y2 - 9 July 2019 through 11 July 2019

ER -

Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I

Abstract

Conference

Keywords

Access to Document

Fingerprint

Cite this